 Psychedelics company Cybin Inc. CYBN CYBN announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the companys investigational deuterated dimethyltryptamine DMT compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. 